Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DSM Forms 50-50 Joint Venture With Sinochem To Crack Into China's Restricted Anti-Infectives Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Netherlands-based Royal DSM announced Dec. 17 that it reached an agreement with Sinochem Group, one of China's biggest central state-owned enterprises, to form a global 50-50 joint venture for anti-infectives. The two companies expect to close the transaction in Q2 2011

You may also be interested in...



DSM In India Gets Neighborly With Nutritional Ingredient Customers

The Dutch conglomerate DSM will open a dietary supplements manufacturing site in India, where the company forecasts strong growth. While DSM currently distributes ingredients from plants in other countries to India, the facility will provide its customers quicker lead times for customized nutrient blends.

DSM In India Gets Neighborly With Nutritional Ingredient Customers

The Dutch conglomerate DSM will open a dietary supplements manufacturing site in India, where the company forecasts strong growth. While DSM currently distributes ingredients from plants in other countries to India, the facility will provide its customers quicker lead times for customized nutrient blends.

Nutrition Giant DSM Unveils New Indian Site To Gain Local Edge

Dutch conglomerate DSM has established a brand new dietary supplements manufacturing site in India. The company forecasts strong growth in the segment, and the new unit, which will replace imports, is preparing for quicker lead times and localized solutions.

Related Content

Latest News
UsernamePublicRestriction

Register

SC073887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel